Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521022 · ClinicalTrials.gov registry record · Phase 1
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
A Phase 1 study of Amyloidosis; Systemic, sponsored by Attralus.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 11
- Study locations
NCT05521022 is a Phase 1 study of Amyloidosis; Systemic that is actively recruiting participants, run by Attralus. The registered enrollment target is 100 participants. The trial reports 11 study locations across 10 states.
The verdict
NCT05521022, a Phase 1 study of Amyloidosis; Systemic, is actively recruiting participants, sponsored by Attralus.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Conditions Studied
Interventions
- DRUG AT-02
- OTHER AT-02 (Placebo)
Study Locations (11)
Queensland
- Q-Pharm Pty Ltd - Herston
- Princess Alexandra Hospital - Woolloongabba
Kansas
- Midwest Heart and Vascular - Overland Park
Maryland
- Johns Hopkins - Baltimore
Missouri
- St. Luke's Hospital of Kansas City - Kansas City
Ohio
- Cleveland Clinic - Cleveland
Oregon
- OHSU (Oregon Health & Science University) - Portland
Pennsylvania
- Penn Presbyterian Medical Center - Philadelphia
South Australia
- Flinders Medical Centre - Bedford Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2025-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05521022
The ClinicalTrials.gov registry entry for NCT05521022 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Attralus, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyloidosis; Systemic appearing as the primary indexed condition, and to 2 interventions - of which AT-02 is the first listed.
NCT05521022 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Queensland, Kansas, Maryland.
Frequently Asked Questions
What is clinical trial NCT05521022 about?
NCT05521022 is a clinical study titled "Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis". This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects ...
What is the current status of trial NCT05521022?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2022-09-01. Estimated completion is 2025-03-01.
What conditions does trial NCT05521022 study?
This clinical trial studies the following conditions: Amyloidosis; Systemic.
What interventions are being tested in trial NCT05521022?
The interventions under investigation include: AT-02 (DRUG), AT-02 (Placebo) (OTHER).
Who is sponsoring clinical trial NCT05521022?
This trial is sponsored by Attralus, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05521022 being conducted?
This trial has 11 study locations across Kansas, Maryland, Missouri, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis; Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.